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The purpose of our study was to compare long-term safety outcomes (overall survival, disease progression,
and incidence of secondary malignancies) between palifermin and placebo in the prevention of oral mucositis
in patients with hematological malignancies undergoing autologous hematopoietic stem cell transplantation
(HSCT). Patients were enrolled between 1997 and 2005 into 4 phase I to III studies (3 double-blind placebo-
controlled and 1 open-label) conducted at 31 sites in Australia, Europe, and the United States. Survival
outcomes (overall survival, progression-free survival) were compared using hazard ratios (HRs) estimated
with a Cox model that included treatment group, baseline age, disease type, Eastern Cooperative Oncology
Group performance status, country, and presence of prior radiotherapy as covariates. The incidence of sec-
ondary malignancies was compared with a chi-square test. A total of 672 patients were randomized into the
studies (428 palifermin and 244 placebo). The median follow-up time for subjects alive at last visit was
7.9 years (range, .1 to 14.9) for palifermin and 8.8 years (range, .1 to 14.8) for placebo. Palifermin-treated
patients had overall survival (HR, 1.01; 95% conﬁdence interval [CI], .78 to 1.31; P ¼ .921) and progression-
free survival times (HR, 1.04; 95% CI, .83 to 1.31; P ¼ .733) that were comparable with placebo-treated
patients. Secondary malignancies were reported by 13% of palifermin-treated patients versus 11% of pla-
cebo patients (P ¼ .477). Breakdown into secondary hematological malignancies (7% versus 6%) or solid
tumors (6% versus 6%) did not suggest any differences between the treatment groups. After a follow-up of up
to 15 years, comparable long-term safety outcomes (overall survival, progression-free survival, and incidence
of secondary malignancies) were observed for palifermin- and placebo-treated patients undergoing
autologous HSCT.
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Treatments for malignancies with chemotherapeutic
agents and/or radiotherapy are becoming increasingly
effective but are associated with short- and long-term sideedgments on page 168.
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ty for Blood and Marrow Transplantation.effects, including complications such as oral mucositis (OM)
[1]. OM typically appears 7 to 14 days after the start of
chemotherapy or with radiotherapy at a cumulative tissue
dose of 15 Gy to 20 Gy of standard fractionated radiation
therapy [2]. The incidence of ulcerative OM ranges between
20% and 80%, depending on the cancer treatment [3,4], but
patients undergoing chemoradiotherapy for hematological
malignancies have an incidence closer to 100% [5]. Clinical
features of OM include erythema, ulceration, and pseudo-
membrane formation, which can lead to pain, difﬁculty in
swallowing and chewing food, and increased risk of
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therapy interruption and increased antibiotics and narcotics
use, hospitalization time, and overall treatment cost [6].
Over the years, various drugs and methods have been
investigated to treat and prevent OM. For patients under-
going hematopoietic stem cell transplantation (HSCT) for
treatment of chemosensitive malignancies, such as multiple
myeloma and non-Hodgkin and Hodgkin lymphomas, suc-
cessful therapies include oral cryotherapy [7], low-level
light laser therapy [8], and palifermin [1,9]. Palifermin
(Kepivance, Swedish Orphan Biovitrum AB [Sobi], Stock-
holm, Sweden) has been shown to reduce the incidence
and duration of severe OM in patients undergoing HSCT,
improve swallowing problems and nutrition, and decrease
length of hospital stay and narcotic opioid use compared
with placebo [10-14]. However, palifermin had no impact
on rates of infection, dietary intake, or time to engraftment
[12]. Overall, palifermin has been shown to be well toler-
ated and safe for patients in shorter follow-up studies
[5,10,15,16].
Palifermin, which is an N-truncated human keratinocyte
growth factor (KGF) produced by recombinant DNA tech-
nology, has improved protein stability over endogenous
human KGF [17]. It acts physiologically on cells that express
the KGF receptor, stimulating their proliferation, differenti-
ation, and survival [17]. Unlike cells of mesenchymal origin,
cells of the haematopoetic lineage do not express the KGF
receptor, and the administration of pharmacologic doses of
palifermin for the prevention or treatment of OM in patients
with hematologic malignancies is not suspected to have
adverse effects on the promotion of secondary haemato-
logical malignancies. However, the incidence of secondary
malignancies and mortality because of malignancies of
epithelial cell origin could potentially be higher in patients
treated with palifermin.
Regardless, patients undergoing high-dose chemo/
radiotherapy and autologous HSCT are at signiﬁcant risk for
developing a secondary malignancy [18], and because pal-
ifermin is intended as a supportive care agent, it is important
to evaluate its effects on long-term safety outcomes. The
objective of this study was to compare long-term safety
outcomes (overall survival, progression-free survival, and
incidence of secondary malignancies) of palifermin versus
placebo when used to prevent OM in patients with hema-
tological malignancies undergoing autologous HSCT.PATIENTS AND METHODS
Study Design and Participants
Patients with hematological malignancies undergoing high-dose
chemotherapy with or without total body irradiation followed by
autologous HSCT were initially enrolled in 4 phase I to phase III studies
(3 double-blind placebo-controlled studies [5,15,16] and 1 open-label study
(unpublished data)) conducted at 31 sites in Australia, Europe, and the
United States between 1997 and 2005 (Table 1). Patients were eligible for
participation in a long-term follow-up study if they had received at least 1Table 1
Study Descriptions
Study Phase Randomization
(Palifermin:Placebo)
Design
1 [15] I/II 2:1 Double-blind, m
2 [16] II 2:1 Double-blind, m
3 [5] III 1:1 Double-blind, m
4 I N/A Open-label, sing
PK indicates pharmacokinetic.dose of investigational product regardless of treatment group assignment in
any of the 4 parent studies. All subjects were required to give written
informed consent to be enrolled in the parent study as well as in the follow-
up study. Patients were followed from the beginning of the above
mentioned clinical studies to the time of the study closure (2012).Analytic Methods
Demographic data, subject baseline characteristics, and exposure to
investigational product were collected in the parent studies. Demographic
and baseline characteristics were compared between treatment groups
using either a t-test (continuous variables), a chi-square test (categorical
variables), or Fisher’s exact test (categorical variables with small cell size).
Survival status (dead or alive, disease progression or no progression) of
all treated patients were included to their last follow-up time, whether in
the parent study or in the follow-up study. Data on secondary malignancies
were available only for the patients enrolled in the follow-up study and up
until their last follow-up time.
Survival outcomes (overall survival and progression-free survival),
beginning from the date of ﬁrst palifermin infusion, were compared using
hazard ratios (HRs) estimated using a Cox model that included treatment
group, baseline age, disease type (Hodgkin lymphoma, non-Hodgkin lym-
phoma, multiple myeloma, leukemia), Eastern Cooperative Oncology Group
performance status, country, and presence of prior radiotherapy as cova-
riates. Because the covariates included in the Cox models were not pre-
deﬁned, stepwise multivariate Cox models were used as an initial step to
select the covariates to be used in the ﬁnal Coxmodels. All demographic and
baseline characteristics collected in the studies were included in this process
as potential explanatory factors. Forward selection steps followed by back-
ward elimination steps were used on a 2-sided signiﬁcance level of .10 for
both selection and elimination. For time to cancer-related death, deaths
preceded by disease progression or development of a secondary malignancy
were classiﬁed as events, whereas deaths from other reasonswere censored.
For time to nonecancer-related deaths, death preceded by disease pro-
gression or development of a secondary malignancy were censored,
whereas death due to other reasons were classiﬁed as events.
In addition to the HR estimates calculated with the adjusted Cox
model, the survival outcomes were described with unadjusted Kaplan-
Meier plots. Incidence of secondary malignancies was compared using a
chi-square test.RESULTS
A total of 672 patients were randomized to the parent
studies, with 662 patients receiving at least 1 dose of pal-
ifermin or placebo (Figure 1). A total of 543 patients partic-
ipated in the long-term follow-up study and were followed
for secondary malignancies. However, data from all 662
patients were used for the analysis of overall survival and
progression-free survival times.
Overall median follow-up time among the patients who
were alive at the last contact was 8.2 years (range, .1 to 14.9)
for a total of 3557 cumulative follow-up years. Median
follow-up time was 7.9 years (range, .1 to 14.9) for patients in
the palifermin group and 8.8 years (range, .1 to 14.8) for
patients in the placebo group (Table 2). The mean age of
patients was 45 years (Table 3), and the majority were male
(63%), Caucasian (84%), diagnosed with non-Hodgkin lym-
phoma (71%), and had an Eastern Cooperative Oncology
Group performance status of 0 (70%). Compared with the
placebo group, more patients in the palifermin group were
diagnosed with non-Hodgkin lymphoma (73.9% versusStudy Endpoints
ulticenter, dose-escalation Safety and tolerability of palifermin
ulticenter Efﬁcacy and safety of palifermin
ulticenter Efﬁcacy and safety of palifermin
le-center PK proﬁle of palifermin
Table 3
Baseline Demographic and Disease Characteristics (All Treated Patients)
Characteristic Palifermin
(n ¼ 421)
Placebo
(n ¼ 241)
P Value
Age, mean (SD), yr 45.8 (12.5) 45.3 (12.3) .808
Sex, n (%)
Male 251 (59.6) 163 (67.6)
Female 170 (40.4) 78 (32.4) .040
Race, n (%)
Caucasian 346 (82.2) 208 (86.3) .167
Black 32 (7.6) 16 (6.6) .646
Hispanic 27 (6.4) 13 (5.4) .597
Unknown 16 (3.8) 4 (1.7) .122
Diagnosis, n (%)
Hodgkin lymphoma 77 (18.3) 59 (24.5) .058
Non-Hodgkin lymphoma 311 (73.9) 159 (66.0) .031
Multiple myeloma 21 (5.0) 15 (6.2) .500
Acute lymphoblastic leukemia 3 (0.7) 1 (0.4) 1.000
Acute myelogenous leukemia 9 (2.1) 6 (2.5) .770
Chronic lymphocytic leukemia 0 1 (0.4) .364
ECOG Performance Status, n (%)
0 290 (68.9) 174 (72.2) .370
1 125 (29.7) 62 (25.7) .276
2 3 (0.7) 3 (1.2) .673
4 0 1 (0.4) .364
Unknown 3 (0.7) 1 (0.4) 1.000
Presence of prior radiotherapy, n (%) 80 (19.0) 42 (17.4) .615
Country, n (%)
United States 255 (60.6) 162 (67.2) .088
Australia 57 (13.5) 24 (10.0) .176
Belgium 13 (3.1) 4 (1.7) .264
Denmark 7 (1.7) 2 (0.8) .499
France 51 (12.1) 23 (9.5) .313
Germany 20 (4.8) 16 (6.6) .303
Spain 6 (1.4) 2 (0.8) .717
United Kingdom 12 (2.9) 8 (3.3) .734
ECOG indicates Eastern Cooperative Oncology Group.
Study 1
Palifermin: 179
Placebo:     85
Study 2
Palifermin: 117
Placebo:     52
Study 3
Palifermin: 107
Placebo:     107
Study 4
Palifermin: 25 
Placebo:     0
Palifermin
n
Randomized 428
Received study drug 421
Palifermin
n
Chose to parƟcipate in 
follow-up study 345
Placebo
n
Randomized 244
Received study drug 241
Placebo
n
Chose to parƟcipate in 
follow-up study 198
All enrolled paƟents (n = 672)
PaƟents in follow-up study (n = 543)
PaƟents included in the survival analysis (n = 662)
Figure 1. Patient disposition.
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Hodgkin lymphoma (18.3% versus 24.5%; P ¼ .058). Patients
were exposed to 5 mg/kg to 180 mg/kg of palifermin, which
was administered in 1 to 6 daily doses. Average daily dose
level was <60 mg/kg in 14%, 60 mg/kg in 68%, and >60 mg/kg
in 18% of the patients. Patients with prior transplantation
were excluded from the parent studies, with the exception
of second transplantations in tandem transplantations.
Only 1 patient enrolled received a tandem transplantation
regimen, and palifermin was used only during the second
transplantation.
Comparable overall survival times were seen in patients
treated with palifermin versus placebo (HR, 1.01; 95% conﬁ-
dence interval [CI], .78 to 1.31; P ¼ .921) (Figure 2A).
Progression-free survival times were also comparable (HR,
1.04; 95% CI, .83 to 1.31; P ¼ .733) (Figure 2B) between the
treatment groups. In addition, the HRs were comparable
between the 2 treatment groups when analyzed by disease
subgroup (Figure 3). Finally, the placebo and palifermin
groups showed comparable time to cancer-related death
(HR, 1.03; 95% CI, .78 to 1.38) as well as comparable time to
nonecancer-related death (HR, .95; 95% CI, .54 to 1.67). Dif-
ferences in palifermin dose levels (<60 mg/kg/day, 60 mg/kg/
day, and >60 mg/kg/day) had no signiﬁcant effect on overall
survival (P ¼ .258) or progression-free survival (P ¼ .161)
when included as an additional covariate in the Cox model.
Overall, the incidence of secondarymalignancies (Table 4)
was comparable between patients treated with palifermin orTable 2
Follow-up Time
Group Follow-up Time for Patients
Who Were Alive at Last
Contact
Total Cumulative
Follow-up Time
n Median, yr Range, yr n Time, patient yr
Palifermin 247 7.9 .1-14.9 421 2256
Placebo 147 8.8 <.1-14.8 241 1302
Total 394 8.2 <.1-14.9 662 3557placebo (13% versus 11%; P ¼ .477). Comparable results were
also observed between patients treated with palifermin or
placebo when secondary malignancies were further charac-
terized as hematological malignancies (7% versus 6%) or solid
tumors (6% versus 6%) or by location (ie, skin, genitourinary,
gastrointestinal tract) (Table 4).DISCUSSION
The results of this long-term follow-up study show no
difference in overall survival and progression-free survival
between palifermin- and placebo-treated patients with a
hematological malignancies undergoing autologous HSCT.
Furthermore, a comparable number of subjects in the pal-
ifermin and placebo groups developed secondary malig-
nancies during the study, with no difference between the
types (ie, hematological malignancies or solid tumors) or
location of these secondary malignancies, suggesting that
palifermin does not promote the development of secondary
tumors. To our knowledge, this is the ﬁrst long-term follow-
up study of palifermin, and it shows that palifermin has no
adverse effect on long-term disease outcomes in patients
being treated for the prevention of OM while undergoing
HSCT for hematologic malignancies.
Signiﬁcantly more patients diagnosed with non-
Hodgkin lymphoma and numerically fewer patients with
Hodgkin lymphoma were included in the palifermin group
compared with in the placebo group. We found no
differences in outcomes despite the fact that in general,
patients with relapsed non-Hodgkin lymphoma have a
3-year progression-free survival of 44% and patients with
Figure 2. Unadjusted Kaplan-Meier curves for all treated patients for (A) overall survival, and (B) progression-free survival.
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3-year progression-free survival of 66% [19].
Our results are consistent with a small multicenter, non-
randomized, matched control study of 36 patients with a
hematological disease treated with allogeneic HSCT, where
no secondary malignancies were observed 3 years after
cancer treatment in either of the palifermin or placebo
groups [20]. In addition, our study extends the reported
safety observation period from 3 years up to almost 15 years
of patient follow-up.
Because palifermin is an N-truncated human KGF that can
stimulate proliferation, differentiation, and survival of
epithelial cells, the question was raised whether palifermin
can drive tumorigenesis, inhibit cytotoxicity of cancer
treatments, or promote the development of secondary
tumors [21]. This study of up to almost 15 years follow-up
provides the most relevant data from a clinical perspective,demonstrating that patients who are treated with palifermin
have survival times comparable to patients treated with
placebo and that they do not have a higher incidence of
secondary malignancies.
An 18.5 years follow-up study of 800 patients who had
received high-dose chemo/radiotherapy and autologous
HSCT observed that secondary malignancies occurred at a
median of 5.6 years (range, .1 to 14.8) after autologous
HSCT, resulting in a 15-year cumulative incidence of sec-
ondary malignancies of 11% (95% CI, 5% to 18%) [18]. Based
on this study, our study, which has an overall follow-up
time of 14.9 years and a median follow-up time of
8.2 years, should have been able to adequately capture
most of the secondary malignancies and observe an effect
of palifermin, if any.
Some of the limitations of this study include the fact that
the study was not prospectively designed as a noninferiority
Figure 3. Forest plot of overall survival by disease subgroup.
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factors inﬂuencing the incidence of OM. Thus, there may be a
lack of prospective stratiﬁcation in the parent studies for
disease type or other important prognostic factors for dis-
ease progression and survival in this patient population.
However, to account for the lack of prospective stratiﬁcation,
HRs were calculated using a Cox model adjusted for the
prognostic factors. Another limitation is the lack of pre-
speciﬁed criteria for the evaluation of tumor response and
disease progression, especially the accurate determination of
the date of ﬁrst disease progression. Finally, the lack of
integration between the parent studies and the follow-up
study, particularly early in the program, was also a limita-
tion, as subjects enrolled in the parent studies were not
required to participate in the follow-up study. One of the
main strengths of this long-term follow-up study is that
patients were enrolled and followed from multicenter, ran-
domized, placebo-controlled studies.
In conclusion, after a follow-up time of up to 15 years
(corresponding to 3557 patient years), comparable long-
term safety outcomes were observed for palifermin- and
placebo-treated patients undergoing autologous HSCT for
hematological malignancies.Table 4
Number of Patients Reporting Secondary Malignancies
Type of Malignancy, n (%) Palifermin
(n ¼ 345)
Placebo
(n ¼ 198)
At least 1 secondary malignancy 46 (13.3) 22 (11.1)
Secondary hematological malignancy 23 (6.7) 11 (5.6)
Solid tumor 22 (6.4) 11 (5.6)
Skin tumor 10 (2.9) 6 (3.0)
Genitounirary tumor 6 (1.7) 3 (1.5)
Tumor in GI tract 4 (1.2) 3 (1.5)
Other solid tumor* 4 (1.2) 0 (0.0)
Othery 1 (0.3) 1 (0.5)
GI indicates gastrointestinal.
* Lung (n ¼ 2), liver, and liposarcoma.
y Palpable lymph nodes, signiﬁcant residual disease.ACKNOWLEDGMENTS
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